Evidence map›Paper›PMID 32210791›Full record

ArticleFrontiers in aging neuroscience2020

Association Between Parkinson's Disease and Melanoma: Putting the Pieces Together.

Qing Ye, Ya Wen, Nasser Al-Kuwari, Xiqun Chen

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. The Skin-Brain Axis: From UV and Pigmentation to Behaviour Modulation.International journal of molecular sciences · 2024
    Review
  10. Epidemiology of Parkinson's Disease: An Update.Current neurology and neuroscience reports · 2024
    Review
  11. Review
  12. Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023
    Article
  13. Review
  14. OncogenicNeural regeneration research · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qing YeDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Ya WenDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Nasser Al-KuwariDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Xiqun ChenDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

Funding

MC1R Basis of Melanoma-Parkinson's Link and Neuroprotective Potential of MC1RR01NS102735 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, XIQUN · 2018 to 2022
$1.8M
Neuroprotection by MC1R as the basis for the melanoma-Parkinson's disease linkR21NS090246 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, XIQUN · 2015 to 2016
$450k
NINDS NIH HHS R01 NS102735NINDS NIH HHS R21 NS090246
6 · The paper itself

Abstract

Patients with Parkinson's disease (PD) generally have reduced risk of developing many types of cancers, except melanoma-a malignant tumor of melanin-producing cells in the skin. For decades, a large number of epidemiological studies have reported that the occurrence of melanoma is higher than expected among subjects with PD, and the occurrence of PD is reciprocally higher than expected among patients with melanoma. More recent epidemiological studies further indicated a bidirectional association, not only in the patients themselves but also in their relatives. This association between PD and melanoma offers a unique opportunity to understand PD. Here, we summarize epidemiological, clinical, and biological evidence in regard to shared risk factors and possible underlying mechanisms for these two seemingly distinct conditions.

Indexed as

cancermelanomaParkinson’s diseasepigmentationrisk factors

Identifiers

PMID32210791
PMCPMC7076116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.